Active not recruiting
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis
I4V-MC-JAIX - ClinicalTrials.gov - NCT03559270
This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD), who have completed participation in study BREEZE-AD5/Study JAIW (NCT03435081).
How long will I be in the trial?
This 204-week outpatient study, includes a treatment period of approximately 200-weeks and up to 17 planned study visits.
Active not recruiting
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis
I4V-MC-JAIX - ClinicalTrials.gov - NCT03559270
This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD), who have completed participation in study BREEZE-AD5/Study JAIW (NCT03435081).
How long will I be in the trial?
This 204-week outpatient study, includes a treatment period of approximately 200-weeks and up to 17 planned study visits.
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participants must have completed at least 16 weeks of treatment in study JAIW prior to discontinuation
Female participants must not be pregnant or breastfeeding
Participants must be willing to commit to using birth control for the duration of the study, unless pregnancy is not possible for the participant or the participants female sexual partner
Participants must NOT
Participants must not be enrolled in other studies that may not be compatible with study JAIX.
Participants must not have uncontrolled high blood pressure, heart attack, chest pain, stroke, heart failure or any other serious or unstable disease or infection
Trial Summary
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
Baricitinib
Could I receive a Placebo?
no
Enrollment Goal
380
Trial Dates
June 2018 - May 2022
Trial Phase
3
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participants must have completed at least 16 weeks of treatment in study JAIW prior to discontinuation
Female participants must not be pregnant or breastfeeding
Participants must be willing to commit to using birth control for the duration of the study, unless pregnancy is not possible for the participant or the participants female sexual partner
Participants must NOT
Participants must not be enrolled in other studies that may not be compatible with study JAIX.
Participants must not have uncontrolled high blood pressure, heart attack, chest pain, stroke, heart failure or any other serious or unstable disease or infection
Trial Summary
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
Baricitinib
Could I receive a Placebo?
no
Enrollment Goal
380
Trial Dates
June 2018 - May 2022
Trial Phase
3
Not the right fit? Sign up to receive updates on new Atopic Dermatitis (Eczema) trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
By clicking the checkbox and using the map, you agree to allow Google Maps to collect your personal information in accordance with their Privacy Policy
Atopic Dermatitis (Eczema) Resources
